Japanese phase II study of90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Authors:
Open Access
- 1 January 2009
- journal article
- Published by Wiley in Cancer Science
- Vol. 100 (1) , 158-164
Abstract
There is no data about the efficacy and safety of radioimmunotherapy with 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma pretreated with rituximab‐containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90Y‐ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100–149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y‐ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty‐five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab‐containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67–93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51–81%). The overall response rates in patients pretreated with rituximab‐containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression‐free survival time of the 40 patients who received 90Y‐ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non‐hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y‐ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B‐cell lymphoma, including those pretreated with rituximab‐containing chemotherapy. (ClinicalTrials.gov number NCT00220285) (Cancer Sci 2009; 100: 158–164)Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationBlood, 2007
- Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911Journal of Clinical Oncology, 2006
- Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphomaCancer Science, 2006
- Phase I study of radioimmunotherapy with an anti‐CD20 murine radioimmunoconjugate (90Y‐ibritumomab tiuxetan) in relapsed or refractory indolent B‐cell lymphomaCancer Science, 2005
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular LymphomaJournal of Clinical Oncology, 2005
- Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-UpJournal of Clinical Oncology, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Stage I and II non-hodgkin's lymphomas: Long-term results of radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989